Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Hozzl · 2024-02-06T08:15:30Z

Explore the details of House Bill 6227 Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

2/6/2024, 8:15 AM

Congressional Summary of HR 6227

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 6227

Bill HR 6227 is currently in the status of Bill Introduced since November 3, 2023. Bill HR 6227 was introduced during Congress 118 and was introduced to the House on November 3, 2023. Bill HR 6227's most recent activity was Referred to the Subcommittee on Health. as of November 10, 2023

Bipartisan Support of Bill HR 6227

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 6227

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 6227

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.